What you should know:
1. The Alliance is funding four separate projects; three relate to early-onset CRC and one on personalized treatment options for rectal cancer patients.
2. New York City-based Memorial Sloan Kettering Cancer Center’s J. Joshua Smith, MD, PhD, will use the funds to advance past research on patient-specific rectal cancer organoids, including growing human-specific rectal cancer models in mice to develop and test personalized treatments.
3. Memorial Sloan’s Robin B. Mendelson, MD, will examine the gut microbiome of patients under 50, and compare it to microbiomes of older patients with CRC and microbiomes of young, healthy people.
4. Philadelphia-based Fox Chase Cancer Center’s Joshua Meyer, MD, will describe the genetic and genomic features of CRC patients, and characterize early-onset CRC patients’ biology.
5. New Haven, Conn.-based Yale School of Medicine’s Rosa Maria Munoz Xicola, PhD, will examine how the adenomatous polyposis coli-negative subset of CRCs develop, and whether the APC-negative subset disproportionately impacts African Americans and/or young people.
6. The Alliance aims to invest $10 million in CRC research projects.
More on gastroenterology:
OSU expected to receive approval for ambulatory care center — 3 insights
The Leapfrog Group lifts ASC survey participation cap after ‘overwhelming response
90 benchmarks to know on payer mix in ASCs
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.